Cargando…

Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies

BACKGROUND: The efficacy of bevacizumab combined with erlotinib (B + E) for the treatment of advanced hepatocellular carcinoma, especially for sorafenib-refractory patients, has been observed and evaluated in several trials. We conducted this single arm meta-analysis to generally assess the benefit...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Liyun, Deng, Huan, Lei, Jun, Yi, Fengming, Li, Jine, Fan, Xiu De, Wei, Yiping, Xu, Jianjun, Zhang, Wenxiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437948/ https://www.ncbi.nlm.nih.gov/pubmed/30922256 http://dx.doi.org/10.1186/s12885-019-5487-6

Ejemplares similares

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2018)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Evaluation and Monitoring of Superoxide Dismutase (SOD) Activity and its Clinical Significance in Gastric Cancer: A Systematic Review and Meta-Analysis
por: Li, Jine, et al.
Publicado: (2019)

Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2018)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2019)

Nivolumab provides improved effectiveness and safety compared with docetaxel as a second‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Xu, Zheng, et al.
Publicado: (2019)

Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
por: Gao, Xiaoqiang, et al.
Publicado: (2023)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
por: Okuno, Masayuki, et al.
Publicado: (2023)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis
por: Zhou, Kenan, et al.
Publicado: (2020)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials
por: Liu, Qiangyun, et al.
Publicado: (2021)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

The benefit and risk of nivolumab in non‐small‐cell lung cancer: a single‐arm meta‐analysis of noncomparative clinical studies and randomized controlled trials
por: Zhao, Binghao, et al.
Publicado: (2018)

Talc pleurodesis versus indwelling pleural catheter among patients with malignant pleural effusion: a meta-analysis of randomized controlled trials
por: Wang, Li, et al.
Publicado: (2020)

Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
por: Xin, Yujing, et al.
Publicado: (2022)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Clinical efficacy evaluation of Erlotinib Combined with Concurrent Chemoradiotherapy in the treatment of locally advanced Pancreatic Cancer
por: Liu, Ci, et al.
Publicado: (2022)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2020)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma
por: ZHANG, HUAN-HUAN, et al.
Publicado: (2013)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
por: Hsu, C-H, et al.
Publicado: (2010)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Erlotinib for advanced hepatocellular carcinoma: A systematic review of phase II/III clinical trials
por: Zhang, Jing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_joau2b2r9bkgphecgj240rc0vp